Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review)
International Journal of Molecular Medicine · 21.07.2023 · 52 (3)
DOI: 10.3892/ijmm.2023.5284 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Medicine, online erschienen am 21.07.2023. Verfasst von Suyanee Thongchot und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand. Hauptthemen laut MEDLINE: Phosphoproteins, Breast Neoplasms. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 204 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The benefits of treating several types of cancers using immunotherapy have recently been established. The overexpression of nucleolin (NCL) in a number of types of cancer provides an attractive antigen target for the development of novel anticancer immunotherapeutic treatments. NCL is a multifunctional protein abundantly distributed in the nucleus, cytoplasm and cell membrane. It influences carcinogenesis, and the proliferation, survival and metastasis of cancer cells, leading to cancer progression. Additionally, the meta‑analysis of total and cytoplasmic NCL overexpression indicates a poor prognosis of patients with breast cancer. The AS1411 aptamers currently appear to have therapeutic action in the phase II clinical trial. The authors' research group has recently explored the anticancer function of NCL through the activation of T cells by dendritic cell‑based immunotherapy. The present review describes and discusses the mechanisms through which the multiple functions of NCL can participate in the progression of cancer. In addition, the studies that define the utility of NCL‑dependent anticancer therapies are summarized, with specific focus being paid to cancer immunotherapeutic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
- Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE‑CIT), Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Zitieren
APA
Thongchot, S., Aksonnam, K., Thuwajit, P., Yenchitsomanus, P. T., & Thuwajit, C. (2023). Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review). International Journal of Molecular Medicine, 52(3). https://doi.org/10.3892/ijmm.2023.5284
Vancouver
Thongchot S, Aksonnam K, Thuwajit P, Yenchitsomanus PT, Thuwajit C. Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review). International Journal of Molecular Medicine. 2023;52(3). doi:10.3892/ijmm.2023.5284
BibTeX
@article{Thongchot2023,
author = {Thongchot, Suyanee and Aksonnam, Krittaya and Thuwajit, Peti and Yenchitsomanus, Pa-Thai and Thuwajit, Chanitra},
title = {Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review)},
journal = {International Journal of Molecular Medicine},
year = {2023},
volume = {52},
number = {3},
doi = {10.3892/ijmm.2023.5284}
}
EUVIMED